[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU6773598A - Treatment of gastrointestinal disease with ppar modulators - Google Patents

Treatment of gastrointestinal disease with ppar modulators

Info

Publication number
AU6773598A
AU6773598A AU67735/98A AU6773598A AU6773598A AU 6773598 A AU6773598 A AU 6773598A AU 67735/98 A AU67735/98 A AU 67735/98A AU 6773598 A AU6773598 A AU 6773598A AU 6773598 A AU6773598 A AU 6773598A
Authority
AU
Australia
Prior art keywords
treatment
gastrointestinal disease
ppar modulators
ppar
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67735/98A
Inventor
Johan Auwerx
Michael R Briggs
Anne-Marie Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Ligand Pharmaceuticals Inc
Original Assignee
Institut Pasteur de Lille
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Ligand Pharmaceuticals Inc filed Critical Institut Pasteur de Lille
Publication of AU6773598A publication Critical patent/AU6773598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU67735/98A 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators Abandoned AU6773598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4137297P 1997-03-26 1997-03-26
US60041372 1997-03-26
PCT/US1998/005852 WO1998043081A1 (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Publications (1)

Publication Number Publication Date
AU6773598A true AU6773598A (en) 1998-10-20

Family

ID=21916159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67735/98A Abandoned AU6773598A (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Country Status (2)

Country Link
AU (1) AU6773598A (en)
WO (1) WO1998043081A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
MXPA01009127A (en) * 1999-03-11 2003-07-14 Nuclear Receptor Res Ltd Novel ligands of nuclear receptors ppar's.
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
WO2002080899A1 (en) * 2001-03-30 2002-10-17 Eisai Co., Ltd. Remedial agent for digestive disease
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
EP1733237A2 (en) * 2004-03-26 2006-12-20 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
ITMI20041825A1 (en) * 2004-09-24 2004-12-24 Medestea Res & Production Srl RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
EP2363127A1 (en) 2006-01-18 2011-09-07 Evolva SA PPAR Modulators
WO2008089461A1 (en) 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes useful as ppar modulators
CA2676435C (en) 2007-01-18 2015-03-24 Evolva Sa Substituted 1,3-dioxanes useful as ppar modulators
WO2008104305A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Pygm as a biomarker for ppara modulators
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
EA020198B1 (en) 2009-02-16 2014-09-30 Джулиани Интернэшнл Лимитед N-acetyl-(r)-(-)-3-(4-aminophenyl)-2-methoxypropionic acid, pharmaceutical composition comprising same, method of treatment
JP5180978B2 (en) * 2010-02-01 2013-04-10 花王株式会社 Screening method for anti-obesity substances
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN116602950A (en) 2012-02-09 2023-08-18 诺格拉制药有限公司 Methods of treating fibrosis
IN2014DN08157A (en) 2012-04-18 2015-05-01 Nogra Pharma Ltd
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
KR20170091157A (en) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 Pirin polypeptide and immune modulation
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2742514T3 (en) 2015-06-15 2020-02-14 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180012849A (en) 2015-06-15 2018-02-06 4디 파마 리서치 리미티드 Composition Containing Bacterial Strain
PT3209310T (en) 2015-11-20 2018-04-20 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3630137B1 (en) 2017-05-22 2023-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
ES2841902T3 (en) 2017-06-14 2021-07-12 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2855701T3 (en) 2017-06-14 2021-09-24 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3600364T2 (en) 2017-06-14 2020-12-31 4D Pharma Res Ltd Compositions comprising a bacterial strain of the genus Megasphaera and uses thereof
US11905232B2 (en) 2019-02-08 2024-02-20 Nogra Pharma Limited Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN112168820B (en) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 Application of SRCAP ATPase inhibitor in colorectal cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269897A (en) * 1992-08-13 1994-02-23 Merck Frosst Canada Inc Assay to detect peroxisome proliferator activity

Also Published As

Publication number Publication date
WO1998043081A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU6773598A (en) Treatment of gastrointestinal disease with ppar modulators
AU5872696A (en) Endoscope
AU7268298A (en) Differential treatment of prosthetic devices
AU3075895A (en) Endoscope
AU1450900A (en) Methods of treatment of type 2 diabetes
AU6418498A (en) Human genes
AU7592998A (en) Modulators of tissue regeneration
AU5899798A (en) Aminoacyl sulfamides for the treatment of hyperproliferative disorders
AU6928098A (en) Optical modulator
AU3596199A (en) Treatment of celiac disease
AU8329498A (en) Diagnosis of edema
AU3322795A (en) Endoscope
AU1184399A (en) Therapeutic molecules
AU7058000A (en) 13 human colon and colon cancer associated proteins
AU7592398A (en) Human gp12 homolog
AU2105897A (en) Organic photoconductor and treatment therefor
AU1645599A (en) Human matrilin-3
AU8155898A (en) Human preprotachykinin b
AU8557598A (en) Treatment of fluids
AU696976B2 (en) Effluent treatment
AU4124497A (en) Treatment of diabetes
AUPO495397A0 (en) Diagnosis of parasites
AUPO632997A0 (en) Diagnosis of parasites
AUPO948197A0 (en) Diagnosis of parasites
AU2002302012A1 (en) Chromim/biotin treatment of type II diabetes